{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:12:57Z","timestamp":1790280777348,"version":"4.1.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Probiotics & Antimicro. Prot."],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12602-025-10804-y","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:26:22Z","timestamp":1762881982000},"page":"5054-5073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gut Microbiota and Chronic Kidney Disease: A Complex Interplay with Implications for Diagnosis and Treatment"],"prefix":"10.1007","volume":"18","author":[{"given":"Jasleen Kaur","family":"Lamba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanderdeep","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6937-0216","authenticated-orcid":false,"given":"Simran","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"1","key":"10804_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 12(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"10804_CR2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE et al (2024) Kdigo 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"21","key":"10804_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111453","volume":"22","author":"E Gusev","year":"2021","unstructured":"Gusev E, Solomatina L, Zhuravleva Y, Sarapultsev A (2021) \u201cThe pathogenesis of end-stage renal disease from the standpoint of the theory of general pathological processes of inflammation.\u201d Int J Mol Sci 22(21):11453. https:\/\/doi.org\/10.3390\/ijms222111453","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10804_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.37547\/TAJMSPR\/Volume02Issue10-11","volume":"02","author":"SJ Botirovna","year":"2020","unstructured":"Botirovna SJ, Tilavkulovich OA, Abdunosirovich RR (2020) The stages of chronic kidney disease. Am J Med Sci Pharm Res 02(10):71\u201375. https:\/\/doi.org\/10.37547\/TAJMSPR\/Volume02Issue10-11","journal-title":"Am J Med Sci Pharm Res"},{"issue":"48","key":"10804_CR5","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1093\/eurheartj\/ehaa650","volume":"41","author":"AS Levey","year":"2020","unstructured":"Levey AS et al (2020) Nomenclature for kidney function and disease\u2014executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Eur Heart J 41(48):4592\u20134598. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa650","journal-title":"Eur Heart J"},{"key":"10804_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00340","author":"PR Gajjala","year":"2015","unstructured":"Gajjala PR, Sanati M, Jankowski J (2015) Cellular and molecular mechanisms of chronic kidney disease with diabetes mellitus and cardiovascular diseases as its comorbidities. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00340","journal-title":"Front Immunol"},{"issue":"1","key":"10804_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-physiol-020518-114605","volume":"81","author":"WR Zhang","year":"2019","unstructured":"Zhang WR, Parikh CR (2019) Biomarkers of acute and chronic kidney disease. Annu Rev Physiol 81(1):309\u2013333. https:\/\/doi.org\/10.1146\/annurev-physiol-020518-114605","journal-title":"Annu Rev Physiol"},{"issue":"11","key":"10804_CR8","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1161\/HYPERTENSIONAHA.122.18567","volume":"79","author":"KA LaFavers","year":"2022","unstructured":"LaFavers KA, Micanovic R, Sabo AR, Maghak LA, El-Achkar TM (2022) Evolving concepts in uromodulin biology, physiology, and its role in disease: a tale of two forms. Hypertension 79(11):2409\u20132418. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.18567","journal-title":"Hypertension"},{"issue":"4","key":"10804_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12040548","volume":"12","author":"M Mizdrak","year":"2022","unstructured":"Mizdrak M, Kumri\u0107 M, Kurir TT, Bo\u017ei\u0107 J (2022) Emerging biomarkers for early detection of chronic kidney disease. J Pers Med 12(4):548. https:\/\/doi.org\/10.3390\/jpm12040548","journal-title":"J Pers Med"},{"issue":"8","key":"10804_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081702","volume":"18","author":"J Rysz","year":"2017","unstructured":"Rysz J, Gluba-Brz\u00f3zka A, Franczyk B, Jab\u0142onowski Z, Cia\u0142kowska-Rysz A (2017) Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci 18(8):1702. https:\/\/doi.org\/10.3390\/ijms18081702","journal-title":"Int J Mol Sci"},{"key":"10804_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104635","volume":"93","author":"F Bienaim\u00e9","year":"2023","unstructured":"Bienaim\u00e9 F (2023) Combining robust urine biomarkers to assess chronic kidney disease progression. EBioMedicine 93:104635. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104635","journal-title":"EBioMedicine"},{"key":"10804_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.phrs.2019.01.019","volume":"141","author":"RJF Felizardo","year":"2019","unstructured":"Felizardo RJF, Watanabe IKM, Dardi P, Rossoni LV, C\u00e2mara NOS (2019) The interplay among gut microbiota, hypertension and kidney diseases: the role of short-chain fatty acids. Pharmacol Res 141:366\u2013377. https:\/\/doi.org\/10.1016\/j.phrs.2019.01.019","journal-title":"Pharmacol Res"},{"issue":"3","key":"10804_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14030176","volume":"14","author":"S Lohia","year":"2022","unstructured":"Lohia S, Vlahou A, Zoidakis J (2022) Microbiome in chronic kidney disease (CKD): an omics perspective. Toxins (Basel) 14(3):176. https:\/\/doi.org\/10.3390\/toxins14030176","journal-title":"Toxins (Basel)"},{"issue":"1","key":"10804_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00974-4","volume":"7","author":"K Hou","year":"2022","unstructured":"Hou K et al (2022) Microbiota in health and diseases. Signal Transduct Target Ther 7(1):135. https:\/\/doi.org\/10.1038\/s41392-022-00974-4","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10804_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02865-0","volume":"11","author":"B Gao","year":"2021","unstructured":"Gao B et al (2021) \u201cButyrate producing microbiota are reduced in chronic kidney diseases.\u201d Sci Rep 11(1):23530. https:\/\/doi.org\/10.1038\/s41598-021-02865-0","journal-title":"Sci Rep"},{"issue":"5","key":"10804_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051948","volume":"12","author":"L Voroneanu","year":"2023","unstructured":"Voroneanu L et al (2023) Gut microbiota in chronic kidney disease: from composition to modulation towards better outcomes\u2014a systematic review. J Clin Med 12(5):1948. https:\/\/doi.org\/10.3390\/jcm12051948","journal-title":"J Clin Med"},{"key":"10804_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00206","author":"F Li","year":"2019","unstructured":"Li F, Wang M, Wang J, Li R, Zhang Y (2019) Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2019.00206","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10804_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1756-4","volume":"17","author":"Y-Y Chen","year":"2019","unstructured":"Chen Y-Y et al (2019) \u201cMicrobiome-metabolome reveals the contribution of gut-kidney axis on kidney disease.\u201d J Transl Med 17(1):5. https:\/\/doi.org\/10.1186\/s12967-018-1756-4","journal-title":"J Transl Med"},{"issue":"50","key":"10804_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2316579120","volume":"120","author":"SE Winter","year":"2023","unstructured":"Winter SE, B\u00e4umler AJ (2023) \u201cGut dysbiosis: Ecological causes and causative effects on human disease.\u201d Proc Natl Acad Sci U S A 120(50):e2316579120. https:\/\/doi.org\/10.1073\/pnas.2316579120","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10804_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043074","volume":"24","author":"D Dahiya","year":"2023","unstructured":"Dahiya D, Nigam PS (2023) \u201cAntibiotic-therapy-induced gut dysbiosis affecting gut microbiota\u2014brain axis and cognition: restoration by intake of probiotics and synbiotics.\u201d Int J Mol Sci 24(4):3074. https:\/\/doi.org\/10.3390\/ijms24043074","journal-title":"Int J Mol Sci"},{"key":"10804_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104583","volume":"152","author":"K Suganya","year":"2021","unstructured":"Suganya K, Son T, Kim K-W, Koo B-S (2021) Impact of gut microbiota: how it could play roles beyond the digestive system on development of cardiovascular and renal diseases. Microb Pathog 152:104583. https:\/\/doi.org\/10.1016\/j.micpath.2020.104583","journal-title":"Microb Pathog"},{"key":"10804_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.837500","author":"Y Huang","year":"2022","unstructured":"Huang Y, Xin W, Xiong J, Yao M, Zhang B, Zhao J (2022) The intestinal microbiota and metabolites in the gut-kidney-heart axis of chronic kidney disease. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.837500","journal-title":"Front Pharmacol"},{"key":"10804_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122863","volume":"351","author":"A Atzeni","year":"2024","unstructured":"Atzeni A (2024) Gut microbiota dynamics and association with chronic kidney disease: a longitudinal study within the PREDIMED-Plus trial. Life Sci 351:122863. https:\/\/doi.org\/10.1016\/j.lfs.2024.122863","journal-title":"Life Sci"},{"key":"10804_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1363276","author":"Y Zhang","year":"2024","unstructured":"Zhang Y et al (2024) Uncovering specific taxonomic and functional alteration of gut microbiota in chronic kidney disease through 16S rRNA data. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2024.1363276","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10804_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02094-5","volume":"21","author":"Y Matsuo","year":"2021","unstructured":"Matsuo Y et al (2021) Full-length 16S rRNA gene amplicon analysis of human gut microbiota using MinION\u2122 nanopore sequencing confers species-level resolution. BMC Microbiol 21(1):35. https:\/\/doi.org\/10.1186\/s12866-021-02094-5","journal-title":"BMC Microbiol"},{"issue":"D1","key":"10804_CR26","doi-asserted-by":"publisher","first-page":"D717","DOI":"10.1093\/nar\/gkac871","volume":"51","author":"C Qi","year":"2023","unstructured":"Qi C et al (2023) gutMDisorder v2.0: a comprehensive database for dysbiosis of gut microbiota in phenotypes and interventions. Nucleic Acids Res 51(D1):D717\u2013D722. https:\/\/doi.org\/10.1093\/nar\/gkac871","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10804_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12060412","volume":"12","author":"RS da Cunha","year":"2020","unstructured":"da Cunha RS, Santos AF, Barreto FC, Stinghen AEM (2020) How do uremic toxins affect the endothelium? Toxins (Basel) 12(6):412. https:\/\/doi.org\/10.3390\/toxins12060412","journal-title":"Toxins (Basel)"},{"issue":"2","key":"10804_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13020142","volume":"13","author":"YJ Lim","year":"2021","unstructured":"Lim YJ, Sidor NA, Tonial NC, Che A, Urquhart BL (2021) Uremic toxins in the progression of chronic kidney disease and cardiovascular disease: mechanisms and therapeutic targets. Toxins (Basel) 13(2):142. https:\/\/doi.org\/10.3390\/toxins13020142","journal-title":"Toxins (Basel)"},{"issue":"6","key":"10804_CR29","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1111\/brv.12765","volume":"96","author":"P Kumar","year":"2021","unstructured":"Kumar P, Lee J, Lee J (2021) Diverse roles of microbial indole compounds in eukaryotic systems. Biol Rev 96(6):2522\u20132545. https:\/\/doi.org\/10.1111\/brv.12765","journal-title":"Biol Rev"},{"issue":"1","key":"10804_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.apsb.2019.05.005","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang J, Yu Z, You G (2020) Insulin-like growth factor 1 modulates the phosphorylation, expression, and activity of organic anion transporter 3 through protein kinase A signaling pathway. Acta Pharm Sin B 10(1):186\u2013194. https:\/\/doi.org\/10.1016\/j.apsb.2019.05.005","journal-title":"Acta Pharm Sin B"},{"issue":"9","key":"10804_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108448","volume":"9","author":"O Ichii","year":"2014","unstructured":"Ichii O et al (2014) Podocyte injury caused by indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand. PLoS ONE 9(9):e108448. https:\/\/doi.org\/10.1371\/journal.pone.0108448","journal-title":"PLoS ONE"},{"key":"10804_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00178","author":"F Xiang","year":"2020","unstructured":"Xiang F et al (2020) Transcriptome profiling reveals indoxyl sulfate should be culpable of impaired T cell function in chronic kidney disease. Front Med Lausanne. https:\/\/doi.org\/10.3389\/fmed.2020.00178","journal-title":"Front Med Lausanne"},{"issue":"6","key":"10804_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10060936","volume":"10","author":"C-L Lu","year":"2021","unstructured":"Lu C-L, Zheng C-M, Lu K-C, Liao M-T, Wu K-L, Ma M-C (2021) Indoxyl-sulfate-induced redox imbalance in chronic kidney disease. Antioxidants 10(6):936. https:\/\/doi.org\/10.3390\/antiox10060936","journal-title":"Antioxidants"},{"key":"10804_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/femsec\/fiy125","author":"Y Saito","year":"2018","unstructured":"Saito Y, Sato T, Nomoto K, Tsuji H (2018) Identification of phenol- and p-cresol-producing intestinal bacteria by using media supplemented with tyrosine and its metabolites. FEMS Microbiol Ecol. https:\/\/doi.org\/10.1093\/femsec\/fiy125","journal-title":"FEMS Microbiol Ecol"},{"issue":"8","key":"10804_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18991","volume":"9","author":"S Amini Khiabani","year":"2023","unstructured":"Amini Khiabani S, Asgharzadeh M, Samadi Kafil H (2023) Chronic kidney disease and gut microbiota. Heliyon 9(8):e18991. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18991","journal-title":"Heliyon"},{"issue":"8","key":"10804_CR36","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1161\/CIRCRESAHA.123.321763","volume":"132","author":"G Glorieux","year":"2023","unstructured":"Glorieux G, Nigam SK, Vanholder R, Verbeke F (2023) Role of the microbiome in gut-heart-kidney cross talk. Circ Res 132(8):1064\u20131083. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.321763","journal-title":"Circ Res"},{"issue":"1","key":"10804_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04455-2","volume":"21","author":"Z Tang","year":"2023","unstructured":"Tang Z, Yu S, Pan Y (2023) The gut microbiome tango in the progression of chronic kidney disease and potential therapeutic strategies. J Transl Med 21(1):689. https:\/\/doi.org\/10.1186\/s12967-023-04455-2","journal-title":"J Transl Med"},{"issue":"6","key":"10804_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/genes14061257","volume":"14","author":"R Di Paola","year":"2023","unstructured":"Di Paola R et al (2023) Possible effects of uremic toxins p-cresol, indoxyl sulfate, p-cresyl sulfate on the development and progression of colon cancer in patients with chronic renal failure. Genes 14(6):1257. https:\/\/doi.org\/10.3390\/genes14061257","journal-title":"Genes"},{"issue":"6","key":"10804_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/ndt\/gfab004","volume":"36","author":"G Glorieux","year":"2021","unstructured":"Glorieux G (2021) Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease. Nephrol Dial Transplant 36(6):998\u20131005. https:\/\/doi.org\/10.1093\/ndt\/gfab004","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10804_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11110635","volume":"11","author":"CC Pelletier","year":"2019","unstructured":"Pelletier CC et al (2019) Elevation of trimethylamine-N-oxide in chronic kidney disease: contribution of decreased glomerular filtration rate. Toxins (Basel) 11(11):635. https:\/\/doi.org\/10.3390\/toxins11110635","journal-title":"Toxins (Basel)"},{"issue":"6","key":"10804_CR41","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/ajcn\/nqaa015","volume":"111","author":"BC Fu","year":"2020","unstructured":"Fu BC et al (2020) Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. Am J Clin Nutr 111(6):1226\u20131234. https:\/\/doi.org\/10.1093\/ajcn\/nqaa015","journal-title":"Am J Clin Nutr"},{"key":"10804_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.929262","author":"Y Zixin","year":"2022","unstructured":"Zixin Y et al (2022) TMAO as a potential biomarker and therapeutic target for chronic kidney disease: a review. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.929262","journal-title":"Front Pharmacol"},{"issue":"1","key":"10804_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-022-00273-4","volume":"8","author":"Y-Y Cai","year":"2022","unstructured":"Cai Y-Y et al (2022) Integrated metagenomics identifies a crucial role for trimethylamine-producing Lachnoclostridium in promoting atherosclerosis. NPJ Biofilms Microbiomes 8(1):11. https:\/\/doi.org\/10.1038\/s41522-022-00273-4","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10804_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085041","volume":"14","author":"J Zhen","year":"2023","unstructured":"Zhen J (2023) \u201cThe gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases.\u201d Front Endocrinol (Lausanne) 14:1085041. https:\/\/doi.org\/10.3389\/fendo.2023.1085041","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10804_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80063-0","volume":"11","author":"W Zhang","year":"2021","unstructured":"Zhang W et al (2021) Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. Sci Rep 11(1):518. https:\/\/doi.org\/10.1038\/s41598-020-80063-0","journal-title":"Sci Rep"},{"key":"10804_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1075641","author":"KH Mutengo","year":"2023","unstructured":"Mutengo KH, Masenga SK, Mweemba A, Mutale W, Kirabo A (2023) Gut microbiota dependant trimethylamine N-oxide and hypertension. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2023.1075641","journal-title":"Front Physiol"},{"issue":"1","key":"10804_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000519603","volume":"47","author":"Y Lai","year":"2022","unstructured":"Lai Y et al (2022) Trimethylamine-N-oxide aggravates kidney injury via activation of p38\/MAPK signaling and upregulation of HuR. Kidney Blood Press Res 47(1):61\u201371. https:\/\/doi.org\/10.1159\/000519603","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"10804_CR48","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/advances\/nmz127","volume":"11","author":"K Gao","year":"2020","unstructured":"Gao K, Mu C, Farzi A, Zhu W (2020) Tryptophan metabolism: a link between the gut microbiota and brain. Adv Nutr 11(3):709\u2013723. https:\/\/doi.org\/10.1093\/advances\/nmz127","journal-title":"Adv Nutr"},{"issue":"11","key":"10804_CR49","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3390\/toxins12110684","volume":"12","author":"T-H Cheng","year":"2020","unstructured":"Cheng T-H et al (2020) Indoxyl sulfate, a tubular toxin, contributes to the development of chronic kidney disease. Toxins (Basel) 12(11):684. https:\/\/doi.org\/10.3390\/toxins12110684","journal-title":"Toxins (Basel)"},{"key":"10804_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2024.114917","volume":"192","author":"SPRR Nayak","year":"2024","unstructured":"Nayak SPRR et al (2024) Indole-3-acetic acid exposure leads to cardiovascular inflammation and fibrosis in chronic kidney disease rat model. Food Chem Toxicol 192:114917. https:\/\/doi.org\/10.1016\/j.fct.2024.114917","journal-title":"Food Chem Toxicol"},{"key":"10804_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neuro.2019.02.019","volume":"73","author":"Y-T Lin","year":"2019","unstructured":"Lin Y-T et al (2019) Indole-3 acetic acid increased risk of impaired cognitive function in patients receiving hemodialysis. Neurotoxicology 73:85\u201391. https:\/\/doi.org\/10.1016\/j.neuro.2019.02.019","journal-title":"Neurotoxicology"},{"issue":"1","key":"10804_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010148","volume":"12","author":"P-H Wu","year":"2024","unstructured":"Wu P-H et al (2024) Exploring the relationship between gut microbiome composition and blood indole-3-acetic acid in hemodialysis patients. Biomedicines 12(1):148. https:\/\/doi.org\/10.3390\/biomedicines12010148","journal-title":"Biomedicines"},{"issue":"4","key":"10804_CR53","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/toxins12040245","volume":"12","author":"G Glorieux","year":"2020","unstructured":"Glorieux G, Gryp T, Perna A (2020) Gut-derived metabolites and their role in immune dysfunction in chronic kidney disease. Toxins (Basel) 12(4):245. https:\/\/doi.org\/10.3390\/toxins12040245","journal-title":"Toxins (Basel)"},{"key":"10804_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-024-03590-0","author":"Y Garcia-Martinez","year":"2024","unstructured":"Garcia-Martinez Y et al (2024) Does gut microbiota dysbiosis impact the metabolic alterations of hydrogen sulfide and lanthionine in patients with chronic kidney disease? BMC Microbiol. https:\/\/doi.org\/10.1186\/s12866-024-03590-0","journal-title":"BMC Microbiol"},{"issue":"2","key":"10804_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020444","volume":"10","author":"A Coppola","year":"2022","unstructured":"Coppola A et al (2022) Uremic toxin lanthionine induces endothelial cell mineralization in vitro. Biomedicines 10(2):444. https:\/\/doi.org\/10.3390\/biomedicines10020444","journal-title":"Biomedicines"},{"issue":"1","key":"10804_CR56","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1080\/0886022X.2022.2107936","volume":"44","author":"J Feng","year":"2022","unstructured":"Feng J, Lu X, Li H, Wang S (2022) The roles of hydrogen sulfide in renal physiology and disease states. Ren Fail 44(1):1290\u20131309. https:\/\/doi.org\/10.1080\/0886022X.2022.2107936","journal-title":"Ren Fail"},{"issue":"9","key":"10804_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092269","volume":"20","author":"C Vigorito","year":"2019","unstructured":"Vigorito C et al (2019) Uremic toxin lanthionine interferes with the transsulfuration pathway, angiogenetic signaling and increases intracellular calcium. Int J Mol Sci 20(9):2269. https:\/\/doi.org\/10.3390\/ijms20092269","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10804_CR58","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/biomedicines10020331","volume":"10","author":"A Kanwal","year":"2022","unstructured":"Kanwal A, Kanwar N, Bharati S, Srivastava P, Singh SP, Amar S (2022) Exploring new drug targets for type 2 diabetes: success, challenges and opportunities. Biomedicines 10(2):331. https:\/\/doi.org\/10.3390\/biomedicines10020331","journal-title":"Biomedicines"},{"key":"10804_CR59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45615","author":"M Kumar","year":"2023","unstructured":"Kumar M et al (2023) The bidirectional link between diabetes and kidney disease: mechanisms and management. Cureus. https:\/\/doi.org\/10.7759\/cureus.45615","journal-title":"Cureus"},{"issue":"12","key":"10804_CR60","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075\u20133090. https:\/\/doi.org\/10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"key":"10804_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1359432","author":"J-X Yu","year":"2024","unstructured":"Yu J-X et al (2024) Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2024.1359432","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"10804_CR62","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","volume":"16","author":"V Vallon","year":"2020","unstructured":"Vallon V, Thomson SC (2020) The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol 16(6):317\u2013336. https:\/\/doi.org\/10.1038\/s41581-020-0256-y","journal-title":"Nat Rev Nephrol"},{"key":"10804_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.872918","author":"Y Yang","year":"2022","unstructured":"Yang Y, Xu G (2022) Update on pathogenesis of glomerular hyperfiltration in early diabetic kidney disease. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2022.872918","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10804_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","author":"JI Fonseca-Correa","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R (2021) Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med Lausanne. https:\/\/doi.org\/10.3389\/fmed.2021.777861","journal-title":"Front Med Lausanne"},{"issue":"9","key":"10804_CR65","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00424-020-02361-w","volume":"472","author":"V Vallon","year":"2020","unstructured":"Vallon V (2020) Glucose transporters in the kidney in health and disease. Pflugers Arch 472(9):1345\u20131370. https:\/\/doi.org\/10.1007\/s00424-020-02361-w","journal-title":"Pflugers Arch"},{"issue":"4","key":"10804_CR66","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/jdi.13255","volume":"11","author":"R Sano","year":"2020","unstructured":"Sano R, Shinozaki Y, Ohta T (2020) Sodium\u2013glucose cotransporters: functional properties and pharmaceutical potential. J Diabetes Investig 11(4):770\u2013782. https:\/\/doi.org\/10.1111\/jdi.13255","journal-title":"J Diabetes Investig"},{"issue":"Supplement_1","key":"10804_CR67","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.2337\/dc23-S011","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA et al (2023) 11. Chronic kidney disease and risk management: standards of care in diabetes\u20142023. Diabetes Care 46(Supplement_1):S191\u2013S202. https:\/\/doi.org\/10.2337\/dc23-S011","journal-title":"Diabetes Care"},{"issue":"1","key":"10804_CR68","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","volume":"39","author":"CW Mende","year":"2022","unstructured":"Mende CW (2022) Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape. Adv Ther 39(1):148\u2013164. https:\/\/doi.org\/10.1007\/s12325-021-01994-2","journal-title":"Adv Ther"},{"key":"10804_CR69","doi-asserted-by":"publisher","first-page":"239","DOI":"10.12688\/f1000research.20602.1","volume":"9","author":"J Reed","year":"2020","unstructured":"Reed J, Bain S, Kanamarlapudi V (2020) \u201cRecent advances in understanding the role of glucagon-like peptide. F1000Res 9:239. https:\/\/doi.org\/10.12688\/f1000research.20602.1","journal-title":"F1000Res"},{"issue":"no. 6","key":"10804_CR70","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.xkme.2021.07.007","volume":"3","author":"R Daza-Arnedo","year":"2021","unstructured":"Daza-Arnedo R et al (2021) Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: a narrative review. Kidney Med 3(6):1065\u20131073. https:\/\/doi.org\/10.1016\/j.xkme.2021.07.007","journal-title":"Kidney Med"},{"key":"10804_CR71","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.2147\/DMSO.S445114","volume":"17","author":"M Mahzari","year":"2024","unstructured":"Mahzari M et al (2024) Efficacy and safety of the utilization of dipeptidyl peptidase IV inhibitors in diabetic patients with chronic kidney disease: a meta-analysis of randomized clinical trials. Diabetes Metab Syndr Obes 17:1425\u20131440. https:\/\/doi.org\/10.2147\/DMSO.S445114","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"7418","key":"10804_CR72","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","volume":"490","author":"J Qin","year":"2012","unstructured":"Qin J et al (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490(7418):55\u201360. https:\/\/doi.org\/10.1038\/nature11450","journal-title":"Nature"},{"issue":"1","key":"10804_CR73","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1038\/s41598-025-90306-7","volume":"15","author":"S Fu","year":"2025","unstructured":"Fu S, Li F, Yu J, Ma S, Zhang L, Cheng Y (2025) Investigating the role of gut microbiota in diabetic nephropathy through plasma proteome mediated analysis. Sci Rep 15(1):5457. https:\/\/doi.org\/10.1038\/s41598-025-90306-7","journal-title":"Sci Rep"},{"key":"10804_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.977187","author":"Q Lv","year":"2022","unstructured":"Lv Q, Li Z, Sui A, Yang X, Han Y, Yao R (2022) The role and mechanisms of gut microbiota in diabetic nephropathy, diabetic retinopathy and cardiovascular diseases. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2022.977187","journal-title":"Front Microbiol"},{"issue":"5","key":"10804_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054619","volume":"24","author":"K Yamamoto","year":"2023","unstructured":"Yamamoto K, Yamashita M, Oda M, Tjendana Tjhin V, Inagawa H, Soma G-I (2023) Oral administration of lipopolysaccharide enhances insulin signaling-related factors in the KK\/Ay mouse model of type 2 diabetes mellitus. Int J Mol Sci 24(5):4619. https:\/\/doi.org\/10.3390\/ijms24054619","journal-title":"Int J Mol Sci"},{"key":"10804_CR76","doi-asserted-by":"publisher","first-page":"104821","DOI":"10.1016\/j.ebiom.2023.104821","volume":"97","author":"L Crudele","year":"2023","unstructured":"Crudele L, Gadaleta RM, Cariello M, Moschetta A (2023) Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. EBioMedicine 97:104821. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104821","journal-title":"EBioMedicine"},{"key":"10804_CR77","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.medmic.2020.100007","volume":"3","author":"W-W Hung","year":"2020","unstructured":"Hung W-W, Hung W-C (2020) How gut microbiota relate to the oral antidiabetic treatment of type 2 diabetes. Med Microecol 3:100007. https:\/\/doi.org\/10.1016\/j.medmic.2020.100007","journal-title":"Med Microecol"},{"key":"10804_CR78","doi-asserted-by":"publisher","first-page":"113581","DOI":"10.1016\/j.fct.2022.113581","volume":"172","author":"C-Y Tseng","year":"2023","unstructured":"Tseng C-Y, Yu P-R, Hsu C-C, Lin H-H, Chen J-H (2023) The effect of isovitexin on lipopolysaccharide-induced renal injury and inflammation by induction of protective autophagy. Food Chem Toxicol 172:113581. https:\/\/doi.org\/10.1016\/j.fct.2022.113581","journal-title":"Food Chem Toxicol"},{"key":"10804_CR79","doi-asserted-by":"publisher","unstructured":"Salguero M, Al-Obaide M, Singh R, Siepmann T, Vasylyeva T (Aug. 2019) Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med. https:\/\/doi.org\/10.3892\/etm.2019.7943","DOI":"10.3892\/etm.2019.7943"},{"issue":"4","key":"10804_CR80","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/19490976.2020.1732268","volume":"11","author":"Y Tian","year":"2020","unstructured":"Tian Y et al (2020) The microbiome modulating activity of bile acids. Gut Microbes 11(4):979\u2013996. https:\/\/doi.org\/10.1080\/19490976.2020.1732268","journal-title":"Gut Microbes"},{"key":"10804_CR81","doi-asserted-by":"publisher","first-page":"1027212","DOI":"10.3389\/fphar.2022.1027212","volume":"13","author":"R Gao","year":"2022","unstructured":"Gao R et al (2022) Bile acids-gut microbiota crosstalk contributes to the improvement of type 2 diabetes mellitus. Front Pharmacol 13:1027212. https:\/\/doi.org\/10.3389\/fphar.2022.1027212","journal-title":"Front Pharmacol"},{"issue":"4","key":"10804_CR82","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3390\/nu13041104","volume":"13","author":"C Xie","year":"2021","unstructured":"Xie C et al (2021) Role of bile acids in the regulation of food intake, and their dysregulation in metabolic disease. Nutrients 13(4):1104. https:\/\/doi.org\/10.3390\/nu13041104","journal-title":"Nutrients"},{"key":"10804_CR83","doi-asserted-by":"publisher","first-page":"111618","DOI":"10.1016\/j.mce.2022.111618","volume":"548","author":"JYL Chiang","year":"2022","unstructured":"Chiang JYL, Ferrell JM (2022) Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol Cell Endocrinol 548:111618. https:\/\/doi.org\/10.1016\/j.mce.2022.111618","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"10804_CR84","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.3390\/molecules27061983","volume":"27","author":"Y Shulpekova","year":"2022","unstructured":"Shulpekova Y et al (2022) A recent ten-year perspective: bile acid metabolism and signaling. Molecules 27(6):1983. https:\/\/doi.org\/10.3390\/molecules27061983","journal-title":"Molecules"},{"key":"10804_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.632335","author":"MN Huda","year":"2021","unstructured":"Huda MN, Kim M, Bennett BJ (2021) Modulating the microbiota as a therapeutic intervention for type 2 diabetes. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2021.632335","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10804_CR86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4093\/dmj.2019.0043","volume":"43","author":"JM Ferrell","year":"2019","unstructured":"Ferrell JM, Chiang JYL (2019) Understanding bile acid signaling in diabetes: from pathophysiology to therapeutic targets. Diabetes Metab J 43(3):257. https:\/\/doi.org\/10.4093\/dmj.2019.0043","journal-title":"Diabetes Metab J"},{"issue":"4","key":"10804_CR87","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1590\/s0004-2803.230402023-86","volume":"60","author":"LJO de Andrade","year":"2023","unstructured":"de Andrade LJO, de Oliveira GCM, de Oliveira LM (2023) The connection between bile acids and type 2 diabetes mellitus - a review. Arq Gastroenterol 60(4):536\u2013542. https:\/\/doi.org\/10.1590\/s0004-2803.230402023-86","journal-title":"Arq Gastroenterol"},{"issue":"13","key":"10804_CR88","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.7150\/ijbs.44774","volume":"16","author":"A Kumari","year":"2020","unstructured":"Kumari A, Pathak DP, Asthana S (2020) \u201cBile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism.\u201d Int J Biol Sci 16(13):2308\u20132322. https:\/\/doi.org\/10.7150\/ijbs.44774","journal-title":"Int J Biol Sci"},{"issue":"4","key":"10804_CR89","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","volume":"79","author":"D Pugh","year":"2019","unstructured":"Pugh D, Gallacher PJ, Dhaun N (2019) Management of hypertension in chronic kidney disease. Drugs 79(4):365\u2013379. https:\/\/doi.org\/10.1007\/s40265-019-1064-1","journal-title":"Drugs"},{"issue":"8","key":"10804_CR90","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","volume":"132","author":"M Burnier","year":"2023","unstructured":"Burnier M, Damianaki A (2023) Hypertension as cardiovascular risk factor in chronic kidney disease. Circ Res 132(8):1050\u20131063. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.321762","journal-title":"Circ Res"},{"key":"10804_CR91","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2356278","author":"K Gao","year":"2024","unstructured":"Gao K, Wang PX, Mei X, Yang T, Yu K (2024) Untapped potential of gut microbiome for hypertension management. Gut Microbes. https:\/\/doi.org\/10.1080\/19490976.2024.2356278","journal-title":"Gut Microbes"},{"issue":"8","key":"10804_CR92","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/cells12081158","volume":"12","author":"VV Lupu","year":"2023","unstructured":"Lupu VV et al (2023) The implication of the gut microbiome in heart failure. Cells 12(8):1158. https:\/\/doi.org\/10.3390\/cells12081158","journal-title":"Cells"},{"key":"10804_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.730809","author":"Y Wu","year":"2021","unstructured":"Wu Y, Xu H, Tu X, Gao Z (2021) The role of short-chain fatty acids of gut microbiota origin in hypertension. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2021.730809","journal-title":"Front Microbiol"},{"issue":"9","key":"10804_CR94","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41581-021-00429-z","volume":"17","author":"M Carlstr\u00f6m","year":"2021","unstructured":"Carlstr\u00f6m M (2021) Nitric oxide signalling in kidney regulation and cardiometabolic health. Nat Rev Nephrol 17(9):575\u2013590. https:\/\/doi.org\/10.1038\/s41581-021-00429-z","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10804_CR95","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/cphy.c200030","volume":"11","author":"M Ottolini","year":"2021","unstructured":"Ottolini M, Sonkusare SK (2021) The calcium signaling mechanisms in arterial smooth muscle and endothelial cells. Compr Physiol 11(2):1831\u20131869. https:\/\/doi.org\/10.1002\/cphy.c200030","journal-title":"Compr Physiol"},{"issue":"1","key":"10804_CR96","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41392-023-01430-7","volume":"8","author":"J Ma","year":"2023","unstructured":"Ma J et al (2023) Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8(1):168. https:\/\/doi.org\/10.1038\/s41392-023-01430-7","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10804_CR97","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.113.01164","volume":"62","author":"Y Ren","year":"2013","unstructured":"Ren Y, D\u2019Ambrosio MA, Garvin JL, Wang H, Carretero OA (2013) Mechanism of inhibition of tubuloglomerular feedback by CO and cGMP. Hypertension 62(1):99\u2013104. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01164","journal-title":"Hypertension"},{"issue":"6","key":"10804_CR98","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2174\/15701611113116660149","volume":"12","author":"M Burke","year":"2014","unstructured":"Burke M, Pabbidi M, Farley J, Roman R (2014) Molecular mechanisms of renal blood flow autoregulation. Curr Vasc Pharmacol 12(6):845\u2013858. https:\/\/doi.org\/10.2174\/15701611113116660149","journal-title":"Curr Vasc Pharmacol"},{"issue":"Suppl 2","key":"10804_CR99","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.23876\/j.krcp.22.011","volume":"41","author":"ES Pak","year":"2022","unstructured":"Pak ES, Cha JJ, Cha DR, Kanasaki K, Ha H (2022) Adenosine receptors as emerging therapeutic targets for diabetic kidney disease. Kidney Res Clin Pract 41(Suppl 2):S74\u2013S88. https:\/\/doi.org\/10.23876\/j.krcp.22.011","journal-title":"Kidney Res Clin Pract"},{"issue":"4","key":"10804_CR100","doi-asserted-by":"publisher","first-page":"F624","DOI":"10.1152\/ajprenal.00239.2020","volume":"319","author":"L Fan","year":"2020","unstructured":"Fan L et al (2020) Impaired renal hemodynamics and glomerular hyperfiltration contribute to hypertension-induced renal injury. Am J Physiol-Renal Physiol 319(4):F624\u2013F635. https:\/\/doi.org\/10.1152\/ajprenal.00239.2020","journal-title":"Am J Physiol-Renal Physiol"},{"issue":"2","key":"10804_CR101","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/HYPERTENSIONAHA.119.13588","volume":"75","author":"J Wei","year":"2020","unstructured":"Wei J et al (2020) Aging impairs renal autoregulation in mice. Hypertension 75(2):405\u2013412. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13588","journal-title":"Hypertension"},{"key":"10804_CR102","doi-asserted-by":"publisher","first-page":"1101068","DOI":"10.3389\/fphar.2023.1101068","volume":"14","author":"S Alshahrani","year":"2023","unstructured":"Alshahrani S (2023) Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: a comparative review. Front Pharmacol 14:1101068. https:\/\/doi.org\/10.3389\/fphar.2023.1101068","journal-title":"Front Pharmacol"},{"issue":"2","key":"10804_CR103","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jvim.15454","volume":"33","author":"MK Ames","year":"2019","unstructured":"Ames MK, Atkins CE, Pitt B (2019) The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med 33(2):363\u2013382. https:\/\/doi.org\/10.1111\/jvim.15454","journal-title":"J Vet Intern Med"},{"issue":"5","key":"10804_CR104","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2215\/CJN.02920320","volume":"15","author":"M-M Gaudreault-Tremblay","year":"2020","unstructured":"Gaudreault-Tremblay M-M, Foster BJ (2020) Benefits of continuing RAAS inhibitors in advanced CKD. Clin J Am Soc Nephrol 15(5):592\u2013593. https:\/\/doi.org\/10.2215\/CJN.02920320","journal-title":"Clin J Am Soc Nephrol"},{"key":"10804_CR105","doi-asserted-by":"publisher","unstructured":"Mafra D, Kemp JA, Borges NA, Wong M, Stenvinkel P (Aug. 2023) Gut Microbiota interventions to retain residual kidney function. Toxins (Basel) 15(8). https:\/\/doi.org\/10.3390\/toxins15080499","DOI":"10.3390\/toxins15080499"},{"issue":"3","key":"10804_CR106","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00424-020-02352-x","volume":"472","author":"NL Rukavina Mikusic","year":"2020","unstructured":"Rukavina Mikusic NL, Kouyoumdzian NM, Choi MR (2020) Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch 472(3):303\u2013320. https:\/\/doi.org\/10.1007\/s00424-020-02352-x","journal-title":"Pflugers Arch"},{"issue":"19","key":"10804_CR107","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.3390\/nu14194044","volume":"14","author":"N Tian","year":"2022","unstructured":"Tian N, Li L, Ng JK-C, Li PK-T (2022) The potential benefits and controversies of probiotics use in patients at different stages of chronic kidney disease. Nutrients 14(19):4044. https:\/\/doi.org\/10.3390\/nu14194044","journal-title":"Nutrients"},{"issue":"9","key":"10804_CR108","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41575-021-00440-6","volume":"18","author":"S Salminen","year":"2021","unstructured":"Salminen S et al (2021) The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol 18(9):649\u2013667. https:\/\/doi.org\/10.1038\/s41575-021-00440-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10804_CR109","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3390\/clinpract13040080","volume":"13","author":"H Sanekommu","year":"2023","unstructured":"Sanekommu H et al (2023) Probiotics and fecal transplant: an intervention in delaying chronic kidney disease progression? Clin Pract 13(4):881\u2013888. https:\/\/doi.org\/10.3390\/clinpract13040080","journal-title":"Clin Pract"},{"key":"10804_CR110","doi-asserted-by":"publisher","first-page":"119311","DOI":"10.1016\/j.lfs.2021.119311","volume":"273","author":"A Arora","year":"2021","unstructured":"Arora A et al (2021) Unravelling the involvement of gut microbiota in type 2 diabetes mellitus. Life Sci 273:119311. https:\/\/doi.org\/10.1016\/j.lfs.2021.119311","journal-title":"Life Sci"},{"issue":"1","key":"10804_CR111","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.1038\/s41598-025-91033-9","volume":"15","author":"W Anegkamol","year":"2025","unstructured":"Anegkamol W et al (2025) Synbiotics as a novel therapeutic approach for hyperphosphatemia and hyperparathyroidism in chronic kidney disease rats. Sci Rep 15(1):7493. https:\/\/doi.org\/10.1038\/s41598-025-91033-9","journal-title":"Sci Rep"},{"issue":"5","key":"10804_CR112","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1053\/j.jrn.2014.05.006","volume":"24","author":"J Cruz-Mora","year":"2014","unstructured":"Cruz-Mora J et al (2014) Effects of a symbiotic on gut microbiota in Mexican patients with end-stage renal disease. J Ren Nutr 24(5):330\u2013335. https:\/\/doi.org\/10.1053\/j.jrn.2014.05.006","journal-title":"J Ren Nutr"},{"key":"10804_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1434613","author":"C Liu","year":"2024","unstructured":"Liu C, Yang L, Wei W, Fu P (2024) Efficacy of probiotics\/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Front Nutr. https:\/\/doi.org\/10.3389\/fnut.2024.1434613","journal-title":"Front Nutr"},{"issue":"8","key":"10804_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/nu14081637","volume":"14","author":"A De Mauri","year":"2022","unstructured":"De Mauri A et al (2022) Probiotics-supplemented low-protein diet for microbiota modulation in patients with advanced chronic kidney disease (ProLowCKD): results from a placebo-controlled randomized trial. Nutrients 14(8):1637. https:\/\/doi.org\/10.3390\/nu14081637","journal-title":"Nutrients"},{"issue":"11","key":"10804_CR115","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.3390\/ijms25116022","volume":"25","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen S, Weiskirchen R (2024) \u201cEffects of probiotics on gut microbiota: an overview.\u201d Int J Mol Sci 25(11):6022. https:\/\/doi.org\/10.3390\/ijms25116022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10804_CR116","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1159\/000494677","volume":"43","author":"L Jia","year":"2018","unstructured":"Jia L, Jia Q, Yang J, Jia R, Zhang H (2018) Efficacy of probiotics supplementation on chronic kidney disease: a systematic review and meta-analysis. Kidney Blood Press Res 43(5):1623\u20131635. https:\/\/doi.org\/10.1159\/000494677","journal-title":"Kidney Blood Press Res"},{"key":"10804_CR117","doi-asserted-by":"publisher","unstructured":"Chafekar D (Mar. 2025) Optimizing chronic kidney disease management: the potential of a multi-strain probiotic formulation. World J Nephrol 14(1). https:\/\/doi.org\/10.5527\/wjn.v14.i1.101515","DOI":"10.5527\/wjn.v14.i1.101515"},{"issue":"2","key":"10804_CR118","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1053\/j.jrn.2022.07.008","volume":"33","author":"M Mitrovi\u0107","year":"2023","unstructured":"Mitrovi\u0107 M et al (2023) The impact of synbiotic treatment on the levels of gut-derived uremic toxins, inflammation, and gut microbiome of chronic kidney disease patients\u2014a randomized trial. J Ren Nutr 33(2):278\u2013288. https:\/\/doi.org\/10.1053\/j.jrn.2022.07.008","journal-title":"J Ren Nutr"},{"issue":"8","key":"10804_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59081383","volume":"59","author":"T Kuskunov","year":"2023","unstructured":"Kuskunov T, Tilkiyan E, Doykov D, Boyanov K, Bivolarska A, Hristov B (2023) \u201cThe effect of synbiotic supplementation on uremic toxins, oxidative stress, and inflammation in hemodialysis patients\u2014results of an uncontrolled prospective single-arm study.\u201d Medicina (B Aires) 59(8):1383. https:\/\/doi.org\/10.3390\/medicina59081383","journal-title":"Medicina (B Aires)"},{"issue":"no. 3","key":"10804_CR120","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/ndt\/gfq624","volume":"26","author":"I Nakabayashi","year":"2011","unstructured":"Nakabayashi I et al (2011) Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 26(3):1094\u20131098. https:\/\/doi.org\/10.1093\/ndt\/gfq624","journal-title":"Nephrol Dial Transplant"},{"issue":"no. 3","key":"10804_CR121","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1053\/ajkd.2003.50104","volume":"41","author":"F Takayama","year":"2003","unstructured":"Takayama F, Taki K, Niwa T (2003) Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 41(3):S142\u2013S145. https:\/\/doi.org\/10.1053\/ajkd.2003.50104","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10804_CR122","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s00394-018-1785-z","volume":"58","author":"M Simeoni","year":"2019","unstructured":"Simeoni M et al (2019) An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD). Eur J Nutr 58(5):2145\u20132156. https:\/\/doi.org\/10.1007\/s00394-018-1785-z","journal-title":"Eur J Nutr"},{"issue":"2","key":"10804_CR123","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1590\/2175-8239-jbn-2022-0021en","volume":"45","author":"\u00c9MR de Ara\u00fajo","year":"2023","unstructured":"de Ara\u00fajo \u00c9MR, Meneses GC, Carioca AAF, Martins AMC, Daher EDF, da Silva Junior GB (2023) Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial. Braz J Nephrol 45(2):152\u2013161. https:\/\/doi.org\/10.1590\/2175-8239-jbn-2022-0021en","journal-title":"Braz J Nephrol"},{"issue":"11","key":"10804_CR124","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/nep.13549","volume":"24","author":"S Tao","year":"2019","unstructured":"Tao S, Tao S, Cheng Y, Liu J, Ma L, Fu P (2019) Effects of probiotic supplements on the progression of chronic kidney disease: a meta-analysis. Nephrology 24(11):1122\u20131130. https:\/\/doi.org\/10.1111\/nep.13549","journal-title":"Nephrology"},{"key":"10804_CR125","doi-asserted-by":"publisher","unstructured":"Cooper TE et al (Oct. 2023) Synbiotics, prebiotics and probiotics for people with chronic kidney disease. Cochrane Database Syst Rev 2023(10). https:\/\/doi.org\/10.1002\/14651858.CD013631.pub2","DOI":"10.1002\/14651858.CD013631.pub2"},{"issue":"15","key":"10804_CR126","doi-asserted-by":"publisher","first-page":"8347","DOI":"10.1021\/acs.jafc.4c00263","volume":"72","author":"H-W Huang","year":"2024","unstructured":"Huang H-W, Chen M-J (2024) Exploring the preventive and therapeutic mechanisms of probiotics in chronic kidney disease through the gut-kidney axis. J Agric Food Chem 72(15):8347\u20138364. https:\/\/doi.org\/10.1021\/acs.jafc.4c00263","journal-title":"J Agric Food Chem"},{"issue":"no. 1","key":"10804_CR127","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/j.jrn.2022.04.003","volume":"33","author":"C McFarlane","year":"2023","unstructured":"McFarlane C, Kelly JT, Conley M, Johnson DW, Campbell KL (2023) Consumers\u2019 perspectives and experiences of prebiotics and probiotics for gut health in chronic kidney disease. J Ren Nutr 33(1):116\u2013125. https:\/\/doi.org\/10.1053\/j.jrn.2022.04.003","journal-title":"J Ren Nutr"},{"issue":"no. 2","key":"10804_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/nu12020334","volume":"12","author":"H Cena","year":"2020","unstructured":"Cena H, Calder PC (2020) Defining a healthy diet: evidence for the role of contemporary dietary patterns in health and disease. Nutrients 12(2):334. https:\/\/doi.org\/10.3390\/nu12020334","journal-title":"Nutrients"},{"issue":"6","key":"10804_CR129","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.chom.2022.04.016","volume":"30","author":"AM Armet","year":"2022","unstructured":"Armet AM et al (2022) Rethinking healthy eating in light of the gut microbiome. Cell Host Microbe 30(6):764\u2013785. https:\/\/doi.org\/10.1016\/j.chom.2022.04.016","journal-title":"Cell Host Microbe"},{"issue":"2\u20133","key":"10804_CR130","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000355785","volume":"39","author":"E Montemurno","year":"2014","unstructured":"Montemurno E et al (2014) What would you like to eat, Mr CKD microbiota? A Mediterranean diet, please! Kidney Blood Press Res 39(2\u20133):114\u2013123. https:\/\/doi.org\/10.1159\/000355785","journal-title":"Kidney Blood Press Res"},{"key":"10804_CR131","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1897212","author":"A Nogal","year":"2021","unstructured":"Nogal A, Valdes AM, Menni C (2021) The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. Gut Microbes. https:\/\/doi.org\/10.1080\/19490976.2021.1897212","journal-title":"Gut Microbes"},{"issue":"18","key":"10804_CR132","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1056\/NEJMra1700312","volume":"377","author":"K Kalantar-Zadeh","year":"2017","unstructured":"Kalantar-Zadeh K, Fouque D (2017) Nutritional management of chronic kidney disease. N Engl J Med 377(18):1765\u20131776. https:\/\/doi.org\/10.1056\/NEJMra1700312","journal-title":"N Engl J Med"},{"issue":"3","key":"10804_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283389","volume":"18","author":"W Liu","year":"2023","unstructured":"Liu W et al (2023) \u201cChanges in gut microbial community upon chronic kidney disease.\u201d PLoS One 18(3):e0283389. https:\/\/doi.org\/10.1371\/journal.pone.0283389","journal-title":"PLoS One"},{"issue":"1","key":"10804_CR134","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/cells10010114","volume":"10","author":"C-Y Yang","year":"2021","unstructured":"Yang C-Y et al (2021) \u201cSynbiotics alleviate the gut indole load and dysbiosis in chronic kidney disease.\u201d Cells 10(1):114. https:\/\/doi.org\/10.3390\/cells10010114","journal-title":"Cells"},{"issue":"9","key":"10804_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091424","volume":"8","author":"BR Di Iorio","year":"2019","unstructured":"Di Iorio BR et al (2019) Nutritional therapy modulates intestinal microbiota and reduces serum levels of total and free indoxyl sulfate and P-cresyl sulfate in chronic kidney disease (Medika study). J Clin Med 8(9):1424. https:\/\/doi.org\/10.3390\/jcm8091424","journal-title":"J Clin Med"},{"issue":"4","key":"10804_CR136","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.kint.2020.11.006","volume":"99","author":"ZA Massy","year":"2021","unstructured":"Massy ZA, Drueke TB (2021) Diet\u2013microbiota interaction and kidney disease progression. Kidney Int 99(4):797\u2013800. https:\/\/doi.org\/10.1016\/j.kint.2020.11.006","journal-title":"Kidney Int"},{"issue":"12","key":"10804_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/nu14122528","volume":"14","author":"J Bian","year":"2022","unstructured":"Bian J, Liebert A, Bicknell B, Chen X-M, Huang C, Pollock CA (2022) Faecal microbiota transplantation and chronic kidney disease. Nutrients 14(12):2528. https:\/\/doi.org\/10.3390\/nu14122528","journal-title":"Nutrients"},{"key":"10804_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00455","author":"H Wang","year":"2020","unstructured":"Wang H et al (2020) Promising treatment for type 2 diabetes: fecal microbiota transplantation reverses insulin resistance and impaired islets. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2019.00455","journal-title":"Front Cell Infect Microbiol"},{"issue":"no. 2","key":"10804_CR139","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/toxins15020115","volume":"15","author":"G Caggiano","year":"2023","unstructured":"Caggiano G et al (2023) Fecal microbiota transplantation in reducing uremic toxins accumulation in kidney disease: current understanding and future perspectives. Toxins (Basel) 15(2):115. https:\/\/doi.org\/10.3390\/toxins15020115","journal-title":"Toxins (Basel)"},{"issue":"8","key":"10804_CR140","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/nu16081109","volume":"16","author":"GY Arteaga-Muller","year":"2024","unstructured":"Arteaga-Muller GY et al (2024) Changes in the progression of chronic kidney disease in patients undergoing fecal microbiota transplantation. Nutrients 16(8):1109. https:\/\/doi.org\/10.3390\/nu16081109","journal-title":"Nutrients"},{"key":"10804_CR141","doi-asserted-by":"publisher","unstructured":"Liu X et al (Nov. 2022) Fecal microbiota transplantation restores normal fecal composition and delays malignant development of mild chronic kidney disease in rats. Front Microbiol 13. https:\/\/doi.org\/10.3389\/fmicb.2022.1037257","DOI":"10.3389\/fmicb.2022.1037257"},{"issue":"11","key":"10804_CR142","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.2215\/CJN.04480422","volume":"17","author":"D Shankaranarayanan","year":"2022","unstructured":"Shankaranarayanan D, Raj DS (2022) Gut microbiome and kidney disease. Clin J Am Soc Nephrol 17(11):1694\u20131696. https:\/\/doi.org\/10.2215\/CJN.04480422","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10804_CR143","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.chom.2020.05.006","volume":"28","author":"S-Y Ting","year":"2020","unstructured":"Ting S-Y et al (2020) Targeted depletion of bacteria from mixed populations by programmable adhesion with antagonistic competitor cells. Cell Host Microbe 28(2):313-321.e6. https:\/\/doi.org\/10.1016\/j.chom.2020.05.006","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10804_CR144","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12602-023-10041-1","volume":"16","author":"GM Campos","year":"2024","unstructured":"Campos GM et al (2024) Lactococcus lactis as an interleukin delivery system for prophylaxis and treatment of inflammatory and autoimmune diseases. Probiotics Antimicrob Proteins 16(2):352\u2013366. https:\/\/doi.org\/10.1007\/s12602-023-10041-1","journal-title":"Probiotics Antimicrob Proteins"},{"key":"10804_CR145","doi-asserted-by":"publisher","unstructured":"Singh AP (2021) Genomic techniques used to investigate the human gut microbiota. https:\/\/doi.org\/10.5772\/intechopen.91808","DOI":"10.5772\/intechopen.91808"},{"key":"10804_CR146","doi-asserted-by":"publisher","unstructured":"Arnold J, Glazier J, Mimee M (Jul. 2023) Genetic engineering of resident bacteria in the gut microbiome. J Bacteriol 205(7). https:\/\/doi.org\/10.1128\/jb.00127-23","DOI":"10.1128\/jb.00127-23"},{"issue":"5","key":"10804_CR147","doi-asserted-by":"publisher","first-page":"109930","DOI":"10.1016\/j.celrep.2021.109930","volume":"37","author":"KN Lam","year":"2021","unstructured":"Lam KN et al (2021) Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Rep 37(5):109930. https:\/\/doi.org\/10.1016\/j.celrep.2021.109930","journal-title":"Cell Rep"},{"issue":"2","key":"10804_CR148","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41592-018-0301-y","volume":"16","author":"C Ronda","year":"2019","unstructured":"Ronda C, Chen SP, Cabral V, Yaung SJ, Wang HH (2019) Metagenomic engineering of the mammalian gut microbiome in situ. Nat Methods 16(2):167\u2013170. https:\/\/doi.org\/10.1038\/s41592-018-0301-y","journal-title":"Nat Methods"},{"key":"10804_CR149","doi-asserted-by":"publisher","first-page":"837500","DOI":"10.3389\/fphar.2022.837500","volume":"13","author":"Y Huang","year":"2022","unstructured":"Huang Y, Xin W, Xiong J, Yao M, Zhang B, Zhao J (2022) The intestinal microbiota and metabolites in the gut-kidney-heart axis of chronic kidney disease. Front Pharmacol 13:837500. https:\/\/doi.org\/10.3389\/fphar.2022.837500","journal-title":"Front Pharmacol"},{"key":"10804_CR150","doi-asserted-by":"publisher","unstructured":"Laiola M et al (Jun. 2025) \u201cToxic microbiome and progression of chronic kidney disease: insights from a longitudinal CKD-Microbiome Study. Gut, p. gutjnl-2024\u2013334634. https:\/\/doi.org\/10.1136\/gutjnl-2024-334634","DOI":"10.1136\/gutjnl-2024-334634"},{"issue":"9","key":"10804_CR151","doi-asserted-by":"publisher","first-page":"107639","DOI":"10.1016\/j.jdiacomp.2020.107639","volume":"34","author":"AH Abdelhafiz","year":"2020","unstructured":"Abdelhafiz AH, Sinclair AJ (2020) Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - a focus on the new hypoglycaemic therapy. J Diabetes Complications 34(9):107639. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107639","journal-title":"J Diabetes Complications"},{"issue":"7","key":"10804_CR152","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/dom.14696","volume":"24","author":"RA DeFronzo","year":"2022","unstructured":"DeFronzo RA, Bakris GL (2022) Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab 24(7):1197\u20131205. https:\/\/doi.org\/10.1111\/dom.14696","journal-title":"Diabetes Obes Metab"}],"container-title":["Probiotics and Antimicrobial Proteins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-025-10804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12602-025-10804-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-025-10804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:40:48Z","timestamp":1783395648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12602-025-10804-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10804"],"URL":"https:\/\/doi.org\/10.1007\/s12602-025-10804-y","relation":{},"ISSN":["1867-1306","1867-1314"],"issn-type":[{"value":"1867-1306","type":"print"},{"value":"1867-1314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}